Mechano Growth Factor (MGF)
Mechano Growth Factor (MGF) is the C-terminal splice variant of IGF-1 (IGF-1Ec in humans) produced in response to mechanical loading, activating muscle satellite stem cells for local tissue repair with distinct signaling from systemic IGF-1.
Overview
MGF was identified by Geoffrey Goldspink's research group at University College London as a mechano-sensitive IGF-1 splice variant expressed rapidly following mechanical stress on muscle tissue. The IGF-1 gene produces multiple mRNA splice variants, with MGF (IGF-1Ec) distinguished by inclusion of a 49-base-pair insert in exon 5 that introduces a reading frame shift, generating a unique 24-amino-acid C-terminal E peptide. This E peptide is responsible for MGF's distinctive biological activity: preferential activation of muscle satellite (stem) cells during the early proliferative phase of repair, before they differentiate into mature myotubes. The extremely short plasma half-life (~5-7 minutes) limits unmodified MGF to local intramuscular use; PEGylation extends activity for systemic delivery.
Mechanism of Action
MGF signals through the IGF-1 receptor with potency comparable to full-length IGF-1, but its unique C-terminal E peptide confers additional biological activity not shared by other IGF-1 isoforms. The E peptide independently activates satellite cells -- the quiescent muscle stem cells residing between the sarcolemma and basal lamina -- driving them into the cell cycle and stimulating proliferation without premature differentiation. This is mediated through upregulation of Pax7 (satellite cell self-renewal marker) and MyoD (myogenic commitment factor) via PI3K/Akt and MAPK/ERK signaling cascades (Goldspink, 2005).
Critically, MGF acts in temporal sequence with mature IGF-1Ea: following mechanical stress, MGF is expressed first (within hours) to activate and expand the satellite cell pool, followed by IGF-1Ea expression (over days) to drive differentiation and protein synthesis. This temporal partitioning means MGF and mature IGF-1 represent distinct phases of the repair response rather than redundant signals (Hill & Goldspink, 2003).
Reconstitution Calculator
Research
Satellite Cell Activation
Goldspink and colleagues demonstrated that MGF is the primary signal for activating quiescent satellite cells following mechanical loading or muscle damage. In vitro studies show that the MGF E peptide alone (without the mature IGF-1 domain) is sufficient to stimulate satellite cell proliferation, indicating that the C-terminal peptide has independent signaling capacity. This is distinct from mature IGF-1, which more strongly drives terminal differentiation. The implication is that MGF specifically expands the satellite cell pool before committing cells to the myogenic lineage (Yang & Goldspink, 2002).
Mechano-Transduction and Exercise Response
MGF expression is rapidly upregulated in skeletal muscle following resistance exercise, stretch, or injury. Goldspink demonstrated a 25% increase in mean muscle fiber size when MGF was administered in conjunction with exercise protocols in mice. The mechano-sensitive expression of MGF represents a direct link between mechanical loading and the molecular signals that initiate muscle adaptation and repair. MGF expression declines with age, potentially contributing to the reduced regenerative capacity of aged muscle (Goldspink, 2005).
Cardiac Repair
MGF is expressed in cardiac tissue following myocardial infarction, where it activates cardiac stem cells and reduces cardiomyocyte apoptosis. Research from multiple groups demonstrates that MGF administration within hours of ischemic injury improves cardiac stem cell recruitment and reduces infarct size. The cardiac expression pattern mirrors skeletal muscle: rapid MGF upregulation followed by sustained IGF-1Ea expression during the remodeling phase (Hill & Goldspink, 2003).
Neuroprotection
MGF is naturally expressed in the brain following hypoxic injury and is over-expressed in regions of greatest neuron regeneration. Dluzniewska et al. demonstrated that MGF treatment improved muscle weakness and reduced motor neuron loss in mouse models of ALS. Elevated MGF levels in transgenic mice correlated with preserved cognitive function and reduced age-related neurodegeneration (Dluzniewska et al., 2005).
Age-Related Decline
MGF expression decreases significantly with aging, correlating with reduced satellite cell activation and impaired muscle regeneration in elderly individuals. Hill et al. showed that aged muscle produces less MGF in response to mechanical loading compared to young muscle, potentially explaining the blunted hypertrophic response to resistance training observed in older adults. Exogenous MGF administration may partially compensate for this age-related decline (Hill et al., 2003).
Muscle satellite cell activation
MGF (mechano growth factor) is a splice variant of IGF-1 (IGF-1Ec in humans) produced rapidly and transiently after mechanical loading or muscle damage. Its distinguishing feature is a unique C-terminal E-domain peptide generated by a reading-frame shift. Cell-culture and rodent studies from the Goldspink group proposed that the E-peptide alone activates quiescent satellite cells and promotes their proliferation without inducing premature differentiation, temporally preceding the sustained IGF-1Ea response. This model underpins interest in MGF for muscle regeneration.
- MGF E-peptide increased myoblast proliferation while inhibiting differentiation (distinct from mature IGF-1)
- Synthetic MGF-E activated human muscle progenitor cells across donor ages
- Independent replication found no effect of the isolated peptide, so bioactivity remains debated
Regenerative and protective applications
Beyond muscle, preclinical studies have examined MGF in cardiac ischemia (reduced cardiomyocyte apoptosis after infarction), bone, and the nervous system (neuronal survival after ischemic injury). All evidence is from in vitro systems and animal models; there are no human clinical trials of MGF, and pharmacokinetics of the short unstable native peptide (versus PEGylated analogues used in research) are poorly characterized.
- Rodent cardiac and neural injury models suggest anti-apoptotic effects
- Native MGF is short-lived; PEG-MGF is used to extend research half-life
- No regulatory approvals and no human efficacy or safety data exist
Safety Profile
MGF is a naturally occurring splice variant of IGF-1, providing a favorable theoretical safety basis. In animal studies, MGF and PEG-MGF have been administered without significant reported adverse effects at research doses. The extremely short half-life of unmodified MGF (~5-7 minutes) inherently limits systemic exposure and off-target effects. As an IGF-1 pathway activator, theoretical concerns include potential effects on pre-existing malignancies. No human clinical trials have established a comprehensive safety profile for MGF or its PEGylated form.
Clinical Research Protocols
MGF has not been evaluated in formal human clinical trials. Preclinical research protocols include:
- Muscle injury models: Cardiotoxin or barium chloride injection to induce controlled muscle damage in mice, followed by local MGF injection (10-100 mcg/kg). Satellite cell activation assessed via Pax7/MyoD immunostaining at 3-14 days post-injury
- Exercise protocols: MGF administered to mice following resistance loading, with muscle fiber cross-sectional area measured at 2-4 weeks (Goldspink, 2005)
- Cardiac ischemia: MGF delivered via biomaterial scaffolds to the infarct zone within 8 hours of coronary artery ligation in rats, with echocardiographic assessment at 4-8 weeks
Pharmacokinetic Profile
Mechano Growth Factor (MGF) — Pharmacokinetic Curve
Intramuscular injection (local), Subcutaneous (as PEG-MGF)Quick Start
- Route
- Intramuscular injection (local), Subcutaneous (as PEG-MGF)
Research Indications
Primary Research Areas
Preclinical work suggests the MGF E-peptide activates satellite (muscle stem) cells after mechanical damage.
Studied in animal and cell models for delaying age- and disuse-related muscle loss; human evidence absent.
Explored in rodent myocardial infarction models for reducing cardiomyocyte loss.
Investigated in preclinical models of ischemia and motor neuron survival.
Research Protocols
intramuscular Injection
The extremely short plasma half-life (~5-7 minutes) limits unmodified MGF to local intramuscular use; PEGylation extends activity for systemic delivery.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Or barium chloride injection to induce co | 10-100 mcg | Per protocol | — |
subcutaneous Injection
Administered via subcutaneous injection.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Muscle injury models | 10-100 mcg | Per protocol | 3-14 days |
What to Expect
What to Expect
Rapid onset expected; half-life of ~5-7 minutes (unmodified) indicates fast-acting pharmacokinetics
Due to short half-life (~5-7 minutes (unmodified)), effects are expected per-dose; consistent daily administration maintains therapeutic levels
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Human clinical trials conducted
- Naturally occurring compound
- Multiple peer-reviewed studies available
Caution
- Limited human data available
- Short half-life may require frequent dosing
Frequently Asked Questions
References (12)
- [7]
- [8]Yang & Goldspink -- Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation FEBS Lett (2002)
- [10]
- [1]Hill & Goldspink *J Physiol* J Physiol (2003)
- [2]Yang & Goldspink *FEBS Lett* FEBS Lett (2002)
- [3]
- [4]
- [5]
- [6]Philippou et al *In Vivo* In Vivo (2009)
- [10]Kandalla PK, Goldspink G, Butler-Browne G, Mouly V Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages Mechanisms of Ageing and Development (2011)
→ Synthetic MGF E-peptide activated human muscle progenitor (satellite) cells and enhanced their proliferation and fusion potential across donor ages in vitro.
- [11]Qin LL, Li XK, Xu J, et al. Mechano growth factor (MGF) promotes proliferation and inhibits differentiation of porcine satellite cells by down-regulation of key myogenic transcriptional factors Molecular and Cellular Biochemistry (2012)
→ MGF drove satellite cell proliferation while suppressing MyoD/myogenin, keeping cells in a proliferative rather than differentiating state.
- [12]Fornaro M, Hinken AC, Needle S, et al. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells American Journal of Physiology - Endocrinology and Metabolism (2014)
→ A rigorous replication attempt found no proliferative or protective effect of the synthetic MGF C-terminal peptide, highlighting ongoing controversy over its bioactivity.
Mazdutide
Mazdutide (IBI362, also known as LY3305677) is a once-weekly subcutaneous GLP-1/glucagon dual receptor agonist co-developed by Innovent Biologics and Eli Lilly.
MELANOTAN 1
Melanotan I, known by its generic name afamelanotide and brand name Scenesse, is a synthetic tridecapeptide analog of alpha-melanocyte stimulating hormone (alph